Articles

Key View

• The EU has adopted its first common cybersecurity certification scheme, dubbed Cybersecurity Scheme in Common Criteria (EUCC), which is a voluntary program allowing ICT vendors to demonstrate the cyber resilience of their products.
• The development carries multiple significant market implications; we note a potential, long-term

Key View

• Kuwait’s current account surplus will narrow from an estimated 26.4% of GDP in 2023 to 24.9% of GDP in 2024 largely due to higher goods and services imports, as well as a slowdown in primary income credit growth. 
• Meanwhile, the supply of international reserves held at the Central Bank will see only a tepid rise, as authorities will

The Latest: On February 27 2024, Philips launched its new Azurion neuro biplane system, an enhancement to its image-guided therapy system – Azurion. The new system is designed to enhance and speed up minimally invasive diagnosis and treatment of neurovascular disorders, including stroke, aneurysms and other cerebrovascular diseases. The Azurion p

Key View 

• France’s latest framework will promote market development by enhancing pharmaceutical self-reliance and managing drug shortages.
• The strategic roadmap will enhance industrial sovereignty, signaling a commitment to Europe-wide reindustrialisation. 
• Despite the proactive steps taken by France to alleviate drug shortages, the full

Key View

• We have revised up our 2024 average inflation forecast from 260.0% y-o-y to 300%, as the removal of price caps and the end of subsidy schemes have driven inflation higher, more quickly, than we previously expected.
• Fiscal consolidation measures that remove subsidies will see price pressures peak around the middle of year, while those

Key View

• We believe that the Central Bank of Nigeria (CBN) will raise the policy rate to 28.00% by end-2024, following a 400 basis-point hike to 22.75% in February, in a bid to address high inflation and weakness in the foreign exchange market. 
• While we do not think that higher interest rates will lead directly to an increase in capital

Key View

• Recent positive regulatory developments in Europe and the US will enhance J&J’s multiple myeloma drug portfolio. 
• J&J’s multiple myeloma drug, Carvykti, will outperform Bristol-Myers Squibb’s Abecma, its closest competitor, further strengthening J&J’s oncology business.
• The FDA’s growing caution of CAR T-cell therapies will pose

The Latest: On February 23 2024, the US FDA approved Simlandi (adalimumab-ryvk), a biosimilar to AbbVie’s blockbuster drug Humira (adalimumab). The approval marks a significant milestone for Teva and its partner, Alvotech, as Simlandi becomes the first high-concentration, citrate-free biosimilar to Humira with an interchangeability designation in

Key View

• Pharmaceutical legislation in Ukraine will align with the EU, benefitting stakeholders.
• Local pharmaceutical production will continue to increase, despite limitations from the war with Russia. 
• Foreign investment in Ukraine’s pharmaceutical industry will help to drive local sales.

Pharmaceutical legislation in Ukraine will align

Key View

• The regulatory and policy environment for artificial intelligence (AI) in the Gulf Cooperation Council (GCC) region is expected to foster further AI adoption and integration into sectors such as automotive manufacturing, underpinned by large public investment funds (PIFs) providing funding and carrying out investments.
• As a result of